��������

Knut Pettersson has over thirty years of experience in the pharmaceutical industry, with a focus on cardiovascular drug development. Knut began their career at AstraZeneca in 1982, and spent nineteen years there working on various projects. In 2001, they left AstraZeneca to join A+ Science as a drug project development consultant. Knut stayed with A+ Science for three years before becoming Chief Scientific Officer at Athera Biotechnologies.

Knut Pettersson was a PhD student in Comparative Physiology at the University of Gothenburg.

Knut Pettersson reports to James Hall, CEO. They work with Susanne Möll - Clinical Project Administration, Anders Bergman - COO.